About this trial
Background: Bilateral myringotomy with tympanostomy tube (BMT) placement is one of the most common pediatric surgical procedures. Despite its brief duration, many children experience significant postoperative pain. Current standard care typically involves intramuscular (IM) administration of an opioid (fentanyl) combined with a non-steroidal anti-inflammatory drug (ketorolac). While this multimodal approach provides adequate pain control for approximately 75% of children, it is associated with opioid-related side effects including respiratory depression, nausea, vomiting, and sedation. Additionally, nearly one-quarter of children still experience moderate-to-severe pain despite this regimen.
The Nerve of Arnold block is a regional anesthesia technique that involves injection of local anesthetic near the auricular branch of the vagus nerve, which provides sensory innervation to the external auditory canal and tympanic membrane. This technique offers the potential for targeted, opioid-sparing analgesia with extended duration and minimal systemic side effects. However, high-quality evidence comparing this regional technique to standard systemic analgesia in pediatric patients is lacking.
Study Objective: This study aims to determine whether the Nerve of Arnold block is non-inferior to the standard combination of IM fentanyl and IM ketorolac in controlling postoperative pain in children undergoing BMT placement.
Study Design: This is a prospective, randomized, double-blind, non-inferiority trial. Three hundred children aged 6 months to 6 years scheduled for bilateral myringotomy with tympanostomy tube placement will be randomized 1:1 to receive either: (1) Standard care: IM fentanyl (1-2 mcg/kg) plus IM ketorolac (0.5 mg/kg) with sham Nerve of Arnold block, or (2) Intervention: Bilateral Nerve of Arnold block with bupivacaine 0.25% plus sham IM injections. Both patients and outcome assessors will be blinded to treatment assignments.
Primary Outcome: The proportion of patients experiencing moderate-to-severe pain (Face, Legs, Activity, Cry, Consolability \[FLACC\] scale score ≥4) in the Post-Anesthesia Care Unit (PACU). Non-inferiority will be declared if the upper bound of the 95% confidence interval for the difference in proportions is less than 10 percentage points.
Secondary Outcomes: Secondary outcomes include mean and maximum FLACC scores, rescue analgesic requirements, respiratory depression, postoperative nausea and vomiting, PACU length of stay, parent satisfaction, and pain at 24 hours postoperatively.
Clinical Significance: If the Nerve of Arnold block is shown to be non-inferior to standard care, it could provide a valuable opioid-sparing alternative for postoperative pain management in pediatric ear surgery, potentially reducing opioid-related adverse events while maintaining effective analgesia. This would be particularly beneficial for patients with contraindications to opioids or NSAIDs and aligns with national efforts to reduce opioid exposure in pediatric populations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Allergy to study medications (fentanyl, ketorolac, bupivacaine)
Trial design
Parallel
Treatments tested in this trial
Fentanyl
DrugIntramuscular fentanyl 2 mcg/kg (maximum 100 mcg) administered after induction of anesthesia
Ketorolac
DrugIntramuscular ketorolac 0.5 mg/kg (maximum 30 mg) administered after induction of anesthesia
Nerve of Arnold Block
Procedure/SurgeryBilateral Nerve of Arnold block with bupivacaine 0.25%, 0.2 mL per side (total 0.4 mL), administered after induction of anesthesia
Sham Intramuscular Injection
Procedure/Surgerysham intramuscular injections with normal saline to maintain blinding
Sham Nerve of Arnold Block
Procedure/SurgeryBilateral sham Nerve of Arnold block with normal saline 0.2 mL per side to maintain blinding
Dexmedetomidine
DrugDexmedetomidine 5 mcg per side (10 mcg total) added to bupivacaine solution for Nerve of Arnold block as adjuvant to prolong block duration
Bupivacaine
DrugBupivacaine 0.25% with epinephrine 1:200,000, 0.2 mL per side (total 0.4 mL, maximum 2.5 mg/kg) for bilateral Nerve of Arnold block
Treatment groups
Trial outcomes
Primary outcomes
Number of Participants with Moderate-to-Severe Pain (FLACC Score ≥4) During PACU Stay
Number of participants experiencing at least one FLACC (Face, Legs, Activity, Cry, Consolability) scale score of 4 or greater during Post-Anesthesia Care Unit stay. FLACC is a validated behavioral pain assessment tool scored 0-10, with scores ≥4 indicating moderate-to-severe pain. FLACC scores assessed every 15 minutes during PACU stay.
Secondary outcomes
Highest FLACC Pain Score During PACU Stay
Number of Participants Requiring Rescue Analgesia
Number of participants requiring at least one dose of rescue analgesic medication for FLACC score ≥4
Number of Participants with Respiratory Depression
Number of participants with oxygen saturation below 95% requiring intervention (supplemental oxygen, stimulation, or airway repositioning)
Number of Participants with Postoperative Nausea and Vomiting
Number of participants experiencing at least one episode of nausea or vomiting
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: